Translating Science into Novel Therapeutics
Our discovery platform provides drug candidates that target specific protein-protein interactions responsible for transcriptional regulation of oncogenic and immune-modulatory proteins.
Unlocking Undruggable Targets to Treat Cancer
Our peptide inhibitors of intracellular protein-protein interactions are designed to attack previously “undruggable targets” in cancer cells, promoting cancer cell death or immune-modulations.
Get to Know Us
ST101 for the Treatment of Solid Tumors
Our lead candidate, ST101, is peptide antagonist of C/EBPβ that was designed to promote cell death of solid tumors including breast cancer, melanoma, prostate cancer, and GBM, as well as hematologic malignancies.
Science Backed by Strong Leadership
Our world-class team is helping us pave the way to providing therapeutics for major unmet medical needs.